Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 28, 2004

View Archived Issues

Bayer presents new Raf kinase inhibitors with potential utility in cancer therapy

Novel tachykinin NK1 antagonists designed at Merck

New NY-ESO-1-derived peptide and its use reported in a recent patent

Santhera claims new calpain inhibitors for muscular dystrophy and other uses

New ALK5 inhibitors covered by Pfizer patent

Novel TNF-alpha and IL-1 production inhibitors discovered at Pliva

Vertex describes Na+ and/or Ca2+ channel blockers for pain and other uses

Small molecule by Avidex blocks release of proinflammatory cytokines

Dual action analgesic with high safety profile

Stalevo study to investigate delaying of motor complications in Parkinson's

SomatoKine designated orphan drug in Europe for extreme insulin resistance

Peregrine discusses Tarvacin IND with FDA

Prasugrel to be studied in PCI patients in phase III trial

Protox signs license agreement for genetically modified Aerolysin protein

Arimoclomol demonstrates potential for type 2 diabetes

Exelixis initiates phase I trial for XL-999

IND filing for phase II lung cancer study of NX-473

Innodia begins phase I trial in Canada for ID-1101

Promising phase II results reported for BAY-43-9006 in advanced kidney cancer

Ralfinamide found effective in the management of neuropathic pain

HCT-3012 reported to reduce systolic blood pressure in patients with osteoarthritis

Zometa receives Japanese approval

Potential therapeutic effects of strontium ranelate in osteoarthritis

New phase I/II study for CYT007-TNFQb for psoriasis

European approval for Emselex

Dapoxetine improves latency time in patients with premature ejaculation

Uridine shows anxiolytic-like effects in rodent models of anxiety

ACAT inhibitor K-10191 shows promise as a plaque-stabilizing antiatherosclerotic agent

Effect of donepezil on cognitive function in MS unclear

Phase I/II trial supports activity of epratuzumab in non-Hodgkin's lymphoma

A 14-year study supports Lp-PLA2 as novel risk factor for CHD / News in Context

Chemokine CCR5 inhibitor provides potent protection from vaginal SHIV transmission

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
Vitesse finesse pays off: DBV wins in peanut allergy phase III
BioWorld
DBV Technologies SA’s pivotal phase III trial with the Viaskin Peanut allergy patch came through for the company, and officials plan a BLA filing with the U.S....
Harbour Biomed closes busy year with $1B+ BMS deal
BioWorld
Harbour Biomed has added another collaboration to its end-of-year dealmaking, this time with Bristol Myers Squibb Co. (BMS) to develop multispecific antibodies....
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...